Abstract
The promising area of lipidomics has received a major interest as exploring panels of lipid biomarkers and their metabolic pathways might contribute to the early diagnosis of Alzheimer's disease allowing novel therapeutic targets. Dysfunctions in lipid metabolism have been associated with metabolic disorders as well as with aging and neurodegenerative diseases. Neurolipidomics is beginning to provide new insights into the pathophysiology of AD through identification of plasma and cerebral lipid mediators and metabolites (lipidome).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
